The OIG has added 18 reviews to its FY 2017 Work Plan – most of which target CMS programs, with a particular emphasis on prescription drug policies. For instance, the OIG now intends to examine the following Medicare and Medicaid topics (among others):

  • Excessive Use of Opioids in Medicare Part D
  • Including Non-Covered Versions When Setting Payment Amounts for Part B Drugs
  • FDA Approval Status of Drugs in the Medicaid Drug Rebate Program
  • Accuracy of Drug Classification Data Used to Collect Medicaid Rebates
  • Reasonable Assumptions in Manufacturer AMP Reporting
  • Review of Quality Measures Data Reported by Accountable Care Organizations in the Medicare Shared Savings Program
  • Trends in Hospice Deficiencies and Complaints

Additional information about each of the new reviews is available on the OIG website.